Total submissions: 4
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV001084742 | SCV000773104 | benign | Hypokalemic periodic paralysis, type 1; Malignant hyperthermia, susceptibility to, 5 | 2024-01-29 | criteria provided, single submitter | clinical testing | |
Ce |
RCV000651253 | SCV001147597 | uncertain significance | not provided | 2018-04-01 | criteria provided, single submitter | clinical testing | |
Ambry Genetics | RCV004601236 | SCV005099761 | uncertain significance | Inborn genetic diseases | 2024-05-14 | criteria provided, single submitter | clinical testing | The c.3761G>A (p.R1254Q) alteration is located in exon 30 (coding exon 30) of the CACNA1S gene. This alteration results from a G to A substitution at nucleotide position 3761, causing the arginine (R) at amino acid position 1254 to be replaced by a glutamine (Q). Based on insufficient or conflicting evidence, the clinical significance of this alteration remains unclear. |
Prevention |
RCV003953182 | SCV004775926 | likely benign | CACNA1S-related disorder | 2020-03-10 | no assertion criteria provided | clinical testing | This variant is classified as likely benign based on ACMG/AMP sequence variant interpretation guidelines (Richards et al. 2015 PMID: 25741868, with internal and published modifications). |